Cite
HARVARD Citation
Xu, C. et al. (2017). Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies. CPT: pharmacometrics & systems pharmacology. pp. 712-718. [Online].